Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$4.50 +28.6%	$1.23	$0.55 ▼ $6.19	$250.43M	-0.07	1.26 million shs	11.49 million shs
KOD Kodiak Sciences	$3.70 -2.1%	$3.85	$1.92 ▼ $11.60	$199.45M	2.27	348,462 shs	275,486 shs
MNPR Monopar Therapeutics	$33.60 -4.0%	$36.75	$1.72 ▼ $54.30	$214.09M	0.99	360,287 shs	567,062 shs
RNXT RenovoRx	$1.28 -5.2%	$1.21	$0.75 ▼ $1.69	$49.37M	1.32	98,216 shs	243,724 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+28.57%	+71.10%	+403.36%	+576.69%	+449,999,900.00%
KOD Kodiak Sciences	-2.12%	+2.21%	+5.71%	+27.15%	+61.57%
MNPR Monopar Therapeutics	-4.03%	+2.25%	+3.51%	-16.69%	+801.41%
RNXT RenovoRx	-5.19%	-7.25%	-1.16%	+28.00%	+13.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
CTOR Citius Oncology	0.4741 of 5 stars	1.0	0.0	0.0	3.8	1.7
KOD Kodiak Sciences	4.3057 of 5 stars	3.0	4.0	4.6	2.8	3.3
MNPR Monopar Therapeutics	2.9818 of 5 stars	3.4	5.0	0.0	2.1	2.5
RNXT RenovoRx	2.9999 of 5 stars	3.5	5.0	0.0	2.7	1.7

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	-33.33% Downside
KOD Kodiak Sciences	2.00	Hold	$9.00	143.24% Upside
MNPR Monopar Therapeutics	2.80	Moderate Buy	$56.50	68.15% Upside
RNXT RenovoRx	3.00	Buy	$7.25	466.41% Upside

Current Analyst Ratings Breakdown

Latest RNXT, MNPR, CTOR, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/28/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
4/4/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/31/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
RNXT RenovoRx	$40K	1,170.24	N/A	N/A	$0.19 per share	6.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-53.88%	-18.86%	N/A
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	8/12/2025 (Estimated)

Latest RNXT, MNPR, CTOR, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
3/31/2025	Q4 2024	RNXT RenovoRx	-$0.12	-$0.13	-$0.01	-$0.12	$0.17 million	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.11	0.36	0.05
KOD Kodiak Sciences	N/A	4.62	4.62
MNPR Monopar Therapeutics	N/A	36.91	36.91
RNXT RenovoRx	N/A	9.07	9.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
KOD Kodiak Sciences	89.06%
MNPR Monopar Therapeutics	1.83%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
KOD Kodiak Sciences	45.90%
MNPR Monopar Therapeutics	20.50%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	71.55 million	68.28 million	N/A
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable

RNXT, MNPR, CTOR, and KOD Headlines

Recent News About These Companies

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires 21,000 Shares of Stock

June 9, 2025 | marketbeat.com

RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen

June 6, 2025 | marketbeat.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

RenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital Markets

June 5, 2025 | marketbeat.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

Le BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisions

May 15, 2025 | fr.investing.com

Transcription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentes

May 15, 2025 | fr.investing.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025 | businesswire.com

Earnings Preview For RenovoRx

May 14, 2025 | benzinga.com

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025 | finance.yahoo.com

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025 | finance.yahoo.com

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRx

April 30, 2025 | zonebourse.comZ

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-Pac

April 29, 2025 | zonebourse.comZ

Johns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréas

April 29, 2025 | fr.investing.com

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

April 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
By Chris Markoch | May 29, 2025
View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
3 Companies to Buy on This Early Cycle Recovery
By Gabriel Osorio-Mazilli | June 3, 2025
View 3 Companies to Buy on This Early Cycle Recovery
Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop

RNXT, MNPR, CTOR, and KOD Company Descriptions

Citius Oncology NASDAQ:CTOR

$4.50 +1.00 (+28.57%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.31 -0.19 (-4.31%)

As of 06/27/2025 08:00 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Kodiak Sciences NASDAQ:KOD

$3.70 -0.08 (-2.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.85 +0.15 (+4.03%)

As of 06/27/2025 05:50 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Monopar Therapeutics NASDAQ:MNPR

$33.60 -1.41 (-4.03%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$33.59 -0.01 (-0.03%)

As of 06/27/2025 05:50 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

RenovoRx NASDAQ:RNXT

$1.28 -0.07 (-5.19%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.07 (+5.39%)

As of 06/27/2025 07:56 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time